Title:
METHODS FOR IMPROVED TREATMENT OF CANCER WITH IRINOTECAN BASED ON MRP1
Document Type and Number:
WIPO Patent Application WO2003013533
Kind Code:
A3
Abstract:
The present invention relates to the use of irinotecan or derivative thereof for the preparation of a pharmaceutical composition for treating cancer, especially, colorectal cancer, cervical cancer, gastric cancer, lung cancer, malignant glioma, ovarian cancer, and pancreatic cancer in a patient having a genotype with a variant allele which comprises a polynucleotide in accordance with the present invention. Preferably, a nucleotide deletion, addition and/or substitution comprised by said polynucleotide results in an altered expression of a variant allele compared to the corresponding wild type allele or an altered activity of the polypeptide encoded by the variant allele compared to the polypeptide encoded by the corresponding wild type allele. Finally, the present invention relates to a method for selecting a suitable therapy for a subject suffering from colorectal cancer, cervical cancer, gastric cancer, lung cancer, malignant glioma, ovarian cancer, and pancreatic cancer.
Inventors:
HEINRICH GUENTHER (DE)
KERB REINHOLD (DE)
KERB REINHOLD (DE)
Application Number:
PCT/EP2002/008200
Publication Date:
October 09, 2003
Filing Date:
July 23, 2002
Export Citation:
Assignee:
EPIDAUROS BIOTECHNOLOGIE AG (DE)
HEINRICH GUENTHER (DE)
KERB REINHOLD (DE)
HEINRICH GUENTHER (DE)
KERB REINHOLD (DE)
International Classes:
C12N15/09; A61K31/235; A61K31/277; A61K31/341; A61K31/343; A61K31/352; A61K31/353; A61K31/409; A61K31/4152; A61K31/4709; A61K31/4741; A61K31/4745; A61K31/49; A61K31/496; A61K31/519; A61K31/565; A61K31/566; A61K31/575; A61K38/00; A61K45/00; A61P1/00; A61P1/18; A61P11/00; A61P15/00; A61P25/00; A61P35/00; A61P43/00; C07D491/052; C07D491/22; C12Q1/68; (IPC1-7): A61K31/4745; A61P35/00
Domestic Patent References:
| WO1998037892A1 | 1998-09-03 | |||
| WO2000037107A2 | 2000-06-29 | |||
| WO2001049299A2 | 2001-07-12 | |||
| WO2001054678A2 | 2001-08-02 | |||
| WO2002028380A2 | 2002-04-11 | |||
| WO2001087306A2 | 2001-11-22 |
Foreign References:
| US6395481B1 | 2002-05-28 |
Other References:
FRIEDMAN HENRY S ET AL: "Irinotecan therapy in adults with recurrent or progressive malignant glioma.", JOURNAL OF CLINICAL ONCOLOGY, vol. 17, no. 5, May 1999 (1999-05-01), pages 1516 - 1525, XP008018482, ISSN: 0732-183X
INNOCENTI F ET AL: "PHARMACOGENETICS OF ANTICANCER AGENTS: LESSONS FROM AMONAFIDE AND IRINOTECAN", DRUG METABOLISM AND DISPOSITION, WILLIAMS AND WILKINS., BALTIMORE, MD, US, vol. 29, no. 4, PART 2, April 2001 (2001-04-01), pages 596 - 600, XP001008560, ISSN: 0090-9556
ANDO Y ET AL: "POLYMORPHISMS OF UDP-GLUCURONOSYLTRANSFERASE GENE AND IRINOTECAN TOXICITY: A PHARMACOGENETIC ANALYSIS", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 60, 15 December 2000 (2000-12-15), pages 6921 - 6926, XP002909302, ISSN: 0008-5472
IYER L ET AL: "GENETIC PREDISPOSITION TO THE METABOLISM OF IRINOTECAN (CPT-11) ROLE OF URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE ISOFORM 1A1 IN THE GLUCURONIDATION OF ITS ACTIVE METABOLITE (SN-38) IN HUMAN LIVER MICROSOMES", JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, vol. 101, no. 4, 15 February 1998 (1998-02-15), pages 847 - 854, XP001120443, ISSN: 0021-9738
INNOCENTI F ET AL: "PHARMACOGENETICS OF ANTICANCER AGENTS: LESSONS FROM AMONAFIDE AND IRINOTECAN", DRUG METABOLISM AND DISPOSITION, WILLIAMS AND WILKINS., BALTIMORE, MD, US, vol. 29, no. 4, PART 2, April 2001 (2001-04-01), pages 596 - 600, XP001008560, ISSN: 0090-9556
ANDO Y ET AL: "POLYMORPHISMS OF UDP-GLUCURONOSYLTRANSFERASE GENE AND IRINOTECAN TOXICITY: A PHARMACOGENETIC ANALYSIS", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 60, 15 December 2000 (2000-12-15), pages 6921 - 6926, XP002909302, ISSN: 0008-5472
IYER L ET AL: "GENETIC PREDISPOSITION TO THE METABOLISM OF IRINOTECAN (CPT-11) ROLE OF URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE ISOFORM 1A1 IN THE GLUCURONIDATION OF ITS ACTIVE METABOLITE (SN-38) IN HUMAN LIVER MICROSOMES", JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, vol. 101, no. 4, 15 February 1998 (1998-02-15), pages 847 - 854, XP001120443, ISSN: 0021-9738
Download PDF:
Previous Patent: PHENYL DERIVATIVES AS FACTOR XA INHIBITORS
Next Patent: METHODS FOR THE TREATMENT OF CANCER WITH IRINOTECAN BASED ON CYP3A5
Next Patent: METHODS FOR THE TREATMENT OF CANCER WITH IRINOTECAN BASED ON CYP3A5